Journal Papers, Abstracts, and Commentaries
|
| |
Multiple ascending dose study of BMS-790052, an NS5A replication
complex inhibitor, in patients
infected
with hepatitis C virus genotype 1.
Nettles RE, Gao M, Bifano M,
et al
Hepatology. 2011 Aug 11
Abstract
Genotypic and phenotypic analysis of variants resistant to
HCV NS5A replication complex inhibitor
BMS-790052: In Vitro and In Vivo correlations.
Fridell RA, Wang C, Sun JH,
Hepatology. 2011 Aug 1.
Abstract
A rugged and accurate liquid chromatography-tandem mass spectrometry
method for quantitative
determination of BMS-790052 in plasma.
Jiang H, Zeng J, Deng Y, et al
J Chromatogr B Analyt Technol Biomed Life Sci.
2011 Jul 15;879(22):2064-72.
Abstract
Distinct functions of NS5A in hepatitis C virus RNA
replication uncovered by studies with the NS5A inhibitor BMS-790052
Fridell RA, Qiu D, Valera L,
et al
J Virol. 2011
Jul;85(14):7312-20
Abstract
The hepatitis C virus NS5A inhibitor (BMS-790052) alters
the subcellular localization of the NS5A non-structural viral protein.
Lee C, Ma H, Hang JQ, et al
Virology. 2011 May 25;414(1):10-8.
Abstract
FULL-TEXT ARTICLE
Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in
an in vitro replicon system.
Fridell RA, Qiu D, Wang C,
et al
Antimicrob Agents Chemother.
2010 Sep;54(9):3641-50
Paper |
Journal Papers, Abstracts, and Commentaries
|
Journal Papers, Abstracts, and Commentaries
|
| |
A WEEK-IN-REVIEW FEATURED
REPORT
Virologic Escape during Danoprevir (ITMN-191/RG7227)
Monotherapy is HCV Subtype
Dependent and Associated with R155K Substitution.
Lim SR, Qin X, Susser S, Nicholas JB,
et
al
Antimicrob Agents Chemother.
2011 Nov 7
Abstract
|
Physiological modeling and assessments of regional drug
bioavailability of danoprevir to determine whether
a controlled release formulation is feasible.
Reddy MB, Connor A, Brennan BJ, et al
Biopharm Drug Dispos.
2011 Jul;32(5):261-75.
Abstract
|
Danoprevir monotherapy decreases inflammatory markers in
patients with chronic hepatitis C virus infection.
Schaefer CJ, Kossen K, Lim SR,
Antimicrob Agents Chemother.
2011 Jul;55(7):3125-32.
Abstract
|
Genotype differences in susceptibility and resistance
development of hepatitis C virus to protease inhibitors
telaprevir
(VX-950) and danoprevir (ITMN-191).
Imhof I, Simmonds P.
Hepatology.
2011 Apr;53(4):1090-9
Abstract
|
A WEEK-IN-REVIEW FEATURED
REPORT
Antiviral activity, safety, and
pharmacokinetics of danoprevir/ritonavir plus PEG-IFN
α-2a/RBV in hepatitis C patients.
Gane EJ, Rouzier R, Stedman C, et al
J Hepatol.
2011 Nov;55(5):972-9.
Abstract
Treatment of chronic hepatitis C patients
with the NS3/4A protease inhibitor danoprevir
(ITMN-191/RG7227) leads to robust reductions in viral RNA: a
phase 1b multiple ascending dose study.
Forestier N, Larrey D, Guyader D,
et al
J Hepatol.
2011 Jun;54(6):1130-6.
Abstract
|
Oral combination therapy with a nucleoside
polymerase inhibitor (RG7128) and danoprevir for chronic
hepatitis C genotype 1 infection (INFORM-1) a randomised,
double-blind, placebo-controlled, dose-escalation trial.
Gane EJ, Roberts SK, Stedman CA, et al
Lancet.
2010 Oct 30;376(9751):1467-75
Abstract
|
Danoprevir, an HCV NS3/4A protease inhibitor, improves
insulin sensitivity in patients with genotype 1
chronic hepatitis C
Moucari R, Forestier N, Larrey D,
et al
Gut.
2010 Dec;59(12):1694-8
Abstract
|
Danoprevir, a small-molecule NS3/4A protease
inhibitor for the potential oral treatment of HCV infection.
Deutsch M, Papatheodoridis GV.
Curr Opin Investig Drugs.
2010 Aug;11(8):951-63
Abstract |
|
|
|
Journal Papers, Abstracts, and Commentaries
|
Journal Papers, Abstracts, and
Commentaries
Journal Papers, Abstracts, and Commentaries
|
Journal Papers, Abstracts, and Commentaries
|
| |
POSTER
Continued Selection with the Acyclic
Nucleoside Phosphonate HCV Inhibitor ODE-(S)-MPMPA in vitro
Results in Reversion to Wild-type NS5B and a Resistant Cell Phenotype
Suggesting a High Barrier to
Resistance
D Wyles, K Jones, N Valiaeva J Beadle
(18th CROI)
PDF Poster
Abstract |
Journal Papers, Abstracts, and Commentaries
|
Journal Papers, Abstracts, and Commentaries
|
Journal Papers, Abstracts, and Commentaries
|
| |
Thymosin alpha1
Billich A.
Curr Opin Investig Drugs 2002 May;3(5):698-707
Abstract
|
Journal Papers, Abstracts, and Commentaries
|
Journal Papers, Abstracts, and Commentaries
|
|
HCV Investigational Drugs |
|
|
|
HCV
Main Page
